Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ella Kozlener"'
Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience
Autor:
Keren Rouvinov, Gal Mazor, Ella Kozlener, Amichay Meirovitz, Noa Shani Shrem, Omar Abu Saleh, Sondos Shalata, Alexander Yakobson, Walid Shalata
Publikováno v:
Journal of Personalized Medicine, Vol 13, Iss 11, p 1623 (2023)
In the treatment of cancer, immune checkpoint inhibitors (ICIs) have demonstrated significantly greater effectiveness compared to conventional cytotoxic or platinum-based chemotherapies. To assess the efficacy of ICI’s in penile squamous cell carci
Externí odkaz:
https://doaj.org/article/78fe63778e0d4e7a84b71bee4ace5160
Autor:
Abed Agbarya, Ina Sarel, Tomer Ziv-Baran, Orna Schwartz, Yelena Shechtman, Ella Kozlener, Rasha Khoury, Mohammad Sheikh-Ahmad, Leonard Saiegh, Forat Swaid, Asala Abu Ahmad, Urska Janzic, Ronen Brenner
Publikováno v:
Diseases, Vol 11, Iss 4, p 128 (2023)
The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the
Externí odkaz:
https://doaj.org/article/4c123148817543a68691080805623b7e
Autor:
Abed Agbarya, Ina Sarel, Tomer Ziv-Baran, Sivan Agranat, Orna Schwartz, Ayelet Shai, Sharon Nordheimer, Shlomit Fenig, Yelena Shechtman, Ella Kozlener, Tarek Taha, Haitam Nasrallah, Roma Parikh, Nadav Elkoshi, Carmit Levy, Rasha Khoury, Ronen Brenner
Publikováno v:
Cancers, Vol 13, Iss 16, p 4191 (2021)
The BNT162b2 vaccine was shown to be highly effective in reducing the risk of COVID-19 infection in healthy individuals and patients with chronic disease. However, there are little data regarding its efficacy in patients treated for cancer. We analyz
Externí odkaz:
https://doaj.org/article/1e255db1a033492f982a82eeb4ec13c6
Autor:
Tarek Taha, Carmit Levy, Roma Parikh, Shlomit Fenig, Ronen Brenner, Abed Agbarya, Sharon Nordheimer, Nadav Elkoshi, Ella Kozlener, Sivan Agranat, Haitam Nasrallah, Ayelet Shai, Tomer Ziv-Baran, Yelena Shechtman, Ina Sarel, Rasha Khoury, Orna Schwartz
Publikováno v:
Cancers
Volume 13
Issue 16
Cancers, Vol 13, Iss 4191, p 4191 (2021)
Volume 13
Issue 16
Cancers, Vol 13, Iss 4191, p 4191 (2021)
The BNT162b2 vaccine was shown to be highly effective in reducing the risk of COVID-19 infection in healthy individuals and patients with chronic disease. However, there are little data regarding its efficacy in patients treated for cancer. We analyz
Autor:
Rasha, Khoury, Miguel, Gorenberg, Sahar, Lazri, Tatiana, Amromin, Ella, Kozlener, Abed, Agbarya
Publikováno v:
Harefuah. 159(12)
Cancer patients are more at risk to contract SARS-CoV-2 and may develop many more severe complications, along with high mortality rates relative to the cancer-free population. The outbreak of the epidemic was characterized by a high rate of infection